

Amendments to the Claims

1- 7. (Canceled)

8. (Withdrawn- Currently amended) A method of ~~treating Claim 7,~~
~~wherein the condition is cardiac arrhythmia; in a mammal which comprises administering a~~
~~compound selected from the group consisting of 7-methoxy-2,3-dimethyl-1-phenyl-2,3-~~
~~dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-~~
~~1-ium chloride; 2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-~~
~~methoxy-1-phenylquinazolin-4(1H)-one; and 3-cyclopropyl-7-methoxy-1-~~
~~phenylquinazoline-2,4(1H,3H)-dione in a therapeutically effective amount.~~

9. (Withdrawn) A method of Claim 8, wherein the cardiac arrhythmia is atrial fibrillation.

10. (Withdrawn) A method of Claim 8, wherein the cardiac arrhythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

11. (Canceled)

12. (Withdrawn- Currently Amended) A method of ~~Claim 11, wherein~~
~~the condition is preventing cardiac arrhythmia, a thromboembolic event, or congestive heart~~
~~failure; which comprises administering a compound selected from the group consisting of 7-~~
~~methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-~~
~~oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride; 2-tert-butyl-7-methoxy-1-~~
~~phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one; and~~
~~3-cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione in an amount that is~~
~~effective at inhibiting K_v1.5.~~

13. (Withdrawn) A method of Claim 12, wherein the cardiac arrhythmia is atrial fibrillation.

14. (Withdrawn) A method of Claim 12, wherein the cardiac arrhythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

15. (Withdrawn) A method of Claim 11, wherein the condition is a thromboembolic event.

16. (Withdrawn) A method of Claim 15, wherein the thromboembolic event is a stroke.

17. (Withdrawn) A method of Claim 11, wherein the condition is congestive heart failure.

18-22. (Canceled)

23. (Previously presented) A compound selected from the group consisting of 7-methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride; 2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one; and 3-Cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione.

24. (Previously presented) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound of Claim 23 or a pharmaceutically acceptable crystal form or hydrate thereof.